Acadian Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.5M | Buy |
25,868
+3,658
| +16% | +$1.71M | 0.02% | 495 |
|
|
2025
Q4 | $10.1M | Buy |
22,210
+21,953
| +8,542% | +$9.46M | 0.02% | 482 |
|
|
2025
Q3 | $99K | Buy |
+257
| New | +$107K | ﹤0.01% | 1529 |
|
|
2025
Q1 | – | Sell |
-2,145
| Closed | -$860K | – | 1828 |
|
|
2024
Q4 | $860K | Sell |
2,145
-3,598
| -63% | -$1.67M | ﹤0.01% | 950 |
|
|
2024
Q3 | $2.66M | Sell |
5,743
-15,348
| -73% | -$7.37M | 0.01% | 666 |
|
|
2024
Q2 | $9.88M | Buy |
21,091
+3,257
| +18% | +$1.41M | 0.03% | 354 |
|
|
2024
Q1 | $7.44M | Sell |
17,834
-697
| -4% | -$295K | 0.03% | 370 |
|
|
2023
Q4 | $7.53M | Sell |
18,531
-5,725
| -24% | -$2.11M | 0.03% | 349 |
|
|
2023
Q3 | $8.43M | Buy |
24,256
+432
| +2% | +$151K | 0.04% | 321 |
|
|
2023
Q2 | $8.37M | Sell |
23,824
-13,296
| -36% | -$4.48M | 0.03% | 331 |
|
|
2023
Q1 | $11.7M | Sell |
37,120
-120,321
| -76% | -$36.1M | 0.05% | 282 |
|
|
2022
Q4 | $45.4M | Buy |
157,441
+35,552
| +29% | +$10.8M | 0.22% | 123 |
|
|
2022
Q3 | $35.3M | Buy |
121,889
+103,314
| +556% | +$29.7M | 0.19% | 130 |
|
|
2022
Q2 | $5.23M | Sell |
18,575
-5,882
| -24% | -$1.57M | 0.03% | 402 |
|
|
2022
Q1 | $6.38M | Buy |
24,457
+15,380
| +169% | +$3.65M | 0.03% | 409 |
|
|
2021
Q4 | $1.99M | Sell |
9,077
-328,874
| -97% | -$64M | 0.01% | 657 |
|
|
2021
Q3 | $61.3M | Buy |
337,951
+88,374
| +35% | +$17.3M | 0.23% | 106 |
|
|
2021
Q2 | $50.3M | Buy |
249,577
+199,401
| +397% | +$41.7M | 0.19% | 129 |
|
|
2021
Q1 | $10.8M | Buy |
50,176
+4,400
| +10% | +$966K | 0.04% | 319 |
|
|
2020
Q4 | $10.8M | Buy |
45,776
+24,272
| +113% | +$5.57M | 0.04% | 324 |
|
|
2020
Q3 | $5.85M | Buy |
21,504
+4,028
| +23% | +$1.11M | 0.02% | 410 |
|
|
2020
Q2 | $5.08M | Buy |
17,476
+12,505
| +252% | +$3.39M | 0.02% | 483 |
|
|
2020
Q1 | $1.18M | Buy |
4,971
+3,784
| +319% | +$868K | 0.01% | 742 |
|
|
2019
Q4 | $260K | Buy |
+1,187
| New | +$240K | ﹤0.01% | 1234 |
|
|
2019
Q2 | – | Sell |
-854
| Closed | -$157K | – | 2057 |
|
|
2019
Q1 | $157K | Sell |
854
-17,962
| -95% | -$3.32M | ﹤0.01% | 1415 |
|
|
2018
Q4 | $3.12M | Sell |
18,816
-4,716
| -20% | -$817K | 0.02% | 473 |
|
|
2018
Q3 | $4.54M | Buy |
23,532
+18,926
| +411% | +$3.37M | 0.02% | 395 |
|
|
2018
Q2 | $784K | Sell |
4,606
-162
| -3% | -$25.1K | ﹤0.01% | 793 |
|
|
2018
Q1 | $777K | Sell |
4,768
-15,022
| -76% | -$2.45M | ﹤0.01% | 768 |
|
|
2017
Q4 | $2.96M | Sell |
19,790
-178,403
| -90% | -$26.4M | 0.01% | 477 |
|
|
2017
Q3 | $30.1M | Sell |
198,193
-22,756
| -10% | -$3.43M | 0.13% | 152 |
|
|
2017
Q2 | $28.5M | Buy |
+220,949
| New | +$26.6M | 0.13% | 159 |
|
|
2015
Q1 | – | Sell |
-1,510
| Closed | -$179K | – | 1476 |
|
|
2014
Q4 | $179K | Buy |
+1,510
| New | +$170K | ﹤0.01% | 903 |
|
Other funds holding VRTX
VCM
VPM
Acadian Asset Management's VRTX Position: Q1 2026 in Review
Acadian Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $1.71M and bringing the position to 25,868 shares worth $11.5M. The position accounts for 0.02% of the portfolio, ranked #495.
Acadian Asset Management first reported a position in VRTX in Q4 2014 and has held it in 33 quarters since. The position peaked at $61.3M in Q3 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Acadian Asset Management held 25,868 shares of Vertex Pharmaceuticals worth $11.5M as of Q1 2026.
- Acadian Asset Management bought 3,658 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.71M.
- Vertex Pharmaceuticals made up 0.02% of Acadian Asset Management's portfolio in Q1 2026, its #495 holding.
- Acadian Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 33 quarters since.
- Acadian Asset Management's Vertex Pharmaceuticals position peaked at $61.3M in Q3 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.